Kondrup Maria, Nygaard Anneli Dowler, Madsen Jonna Skov, Bechmann Troels
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark.
Department of Oncology, Aarhus University Hospital, 8000 Aarhus, Denmark.
Biomed Rep. 2020 Apr;12(4):204-208. doi: 10.3892/br.2020.1277. Epub 2020 Feb 11.
Brain metastases are frequent in patients with lung cancer and a major cause of morbidity and mortality. Finding a biomarker predicting brain metastases could facilitate early start of treatment and thereby reduce morbidity and possibly improve overall survival. Previous studies suggest S100B as a possible biomarker for this purpose. This prospective study enrolled 185 patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC). A total of 22 patients had brain metastases verified by magnetic resonance imaging or computed tomography at the time of enrollment. Serum S100B levels were measured in blood samples collected prior to any treatment from 22 patients who had brain metastases at enrollment and from 50 patients randomly selected from the remaining 163 patients without brain metastases at enrollment. No statistically significant difference was found in the levels of serum S100B between patients with and without brain metastases [range 0.018-0.209 µg/l, mean 0.049 µg/l, 95% confidence interval (CI), 0.032-0.061 µg/l] and (range 0.016-0.130 µg/i, mean 0.044 µg/l, 95% CI, 0.037-0.051 µg/l), respectively, (P=0.852). Univariate analysis of prognostic factors for S100B indicated a correlation (P<0.2) with sex (P=0.088) and histology (adenocarcinoma vs. squamous cell carcinoma/others) (P=0.028). In the multivariate analysis only histology (P=0.029) remained statistically significant. Conclusion: The present study found no significant correlation between the level of serum S100B and the presence of brain metastases in patients with advanced NSCLC. The clear cut-off of S100B in patients with and without brain metastases reported in other studies could not be verified in this study. Further studies investigating the role of S100B as a biomarker for brain metastases in non-small cell lung cancer are warranted.
脑转移在肺癌患者中很常见，是发病和死亡的主要原因。找到一种预测脑转移的生物标志物可以促进治疗的早期开始，从而降低发病率并可能改善总生存期。先前的研究表明S100B可能是用于此目的的生物标志物。这项前瞻性研究纳入了185例新诊断的IV期非小细胞肺癌（NSCLC）患者。共有22例患者在入组时经磁共振成像或计算机断层扫描证实有脑转移。在入组时有脑转移的22例患者以及从其余163例入组时无脑转移的患者中随机选择的50例患者在接受任何治疗之前采集的血样中测量血清S100B水平。有脑转移和无脑转移的患者血清S100B水平无统计学显著差异，分别为[范围0.018 - 0.209μg/l，均值0.049μg/l，95%置信区间（CI），0.032 - 0.061μg/l]和（范围0.016 - 0.130μg/i，均值0.044μg/l，95%CI，0.037 - 0.051μg/l），（P = 0.852）。对S100B预后因素的单因素分析表明与性别（P = 0.088）和组织学（腺癌与鳞状细胞癌/其他）（P = 0.028）存在相关性（P < 0.2）。在多因素分析中，只有组织学（P = 0.029）仍具有统计学显著性。结论：本研究发现晚期NSCLC患者血清S100B水平与脑转移的存在之间无显著相关性。其他研究报道的有脑转移和无脑转移患者中S100B的明确临界值在本研究中无法得到验证。有必要进一步研究S100B作为非小细胞肺癌脑转移生物标志物的作用。
